General Information
Official company information
- Registry ID
-
2024315141Registry ID - A unique identifier for this business
- Company Age
- 2 years
- Registration Date
-
- Business Number (BN)
- 726808504
- City
- ST. ALBERT
-
N/A
- Website
-
Official company website with more information about products, services, and contact details.
About SAVA CORP.
Company profile and description
Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system disorders such as Alzheimer's disease. It's lead therapeutic product candidate is simufilam, a small molecule drug. The company was incorporated in 1998 and is based in Austin, Texas.
Category
Business category and classification details
- Primary Category
- Health & Medical
- Description
- Providers of medical, dental, therapeutic, and other health-related services, including hospitals, clinics, private practices, and pharmacies.
Additional Information
Detailed company information and status
- Version
- 1796881038638579712
- Hierarchy
- parent
- Entity Type
- Alberta Business Corporation
- Display Date
- 2022-05-16
- Jurisdiction
- AB
- Business Number
- 726808504
- MRAS Entity Type
- BCA
Company Contacts
Key contacts and leadership 3 total contacts
| Name & Position | Contact Number | Fax Number | |
|---|---|---|---|
|
J
Jim Kupiec
Chief Medical Officer
|
-
|
-
|
-
|
|
J
Jack Moore
Senior Vice President, Clinical Development
|
-
|
-
|
-
|
|
A
Angélique Bordey
SVP, Neuroscience
|
-
|
-
|
-
|
Similar Companies
Companies in the same industry or category
-
Health & Medical -
Health & Medical -
Health & Medical -
Health & Medical
In the News
Recent media coverage and press mentions
No recent media coverage
No recent news articles found for SAVA CORP.
Social Media
Connect with SAVA CORP.
No social media links available